This month, the AACR's journals editors highlighted studies on U.S. cancer mortality hotspots, chemotherapy-induced hearing loss, and more.
In the second quarter of 2025, the FDA issued 13 new oncology approvals, including options for rare cancers, head...
Clinical trial results reported at the AACR Annual Meeting 2025 showcased new therapeutic approaches for non-small cell lung cancer....
Takeaways from day four of the AACR Annual Meeting 2025 included data on one-dose HPV vaccination, technology advancing research,...
In the final three months of 2024, the FDA issued 15 approvals in oncology, including several therapies that are...
Recent advances in EGFR inhibition include combinations to overcome resistance and approvals for newly diagnosed or early-stage lung cancers.
The AACR Industry Roundtable 2024 focused on topics related to tracking and treating early cancers, including predicting cancer risk...
Researchers are looking into urine tests that could detect cancers earlier, including lung, ovarian, pancreatic, colorectal, and more.
This quarter’s 16 approvals include a first-in-class cell therapeutic, a flurry of new options for EGFR-mutated lung cancer, and...
LGBTQ+ cancer survivors offer lessons learned, and a researcher explains the odds of chronic conditions in LGBTQ+ survivors.